FIELD: medicine.
SUBSTANCE: invention refers to genetic engineering, more specifically to analysing the disorders related to ovarian carcinoma, and may be used in medicine. The method involves determining the methylation status of CpG-dinucleotide in the genome in each sequence of a group of sequences SEQ ID NO:1-10 using a set of probes specific for the above sequences and able to be hybridised with the sequence along the full length. The above sequences are used as a part of a chip for detection, diagnosis and monitoring of the proliferative disorders related to ovarian cell proliferation, as well as for detection of a predisposition to the proliferative disorders, or treatment of the proliferative ovarian disorders.
EFFECT: invention enables identifying the proliferative disorders in ovarian cells and detecting a genetic predisposition to the above disorders.
10 cl, 3 dwg, 2 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF ANALYSIS OF MAMMARY GLAND CANCEROUS DISEASES | 2008 |
|
RU2492243C2 |
| METHODS OF CANCER SCREENING | 2012 |
|
RU2700088C2 |
| DIAGNOSTIC MARKERS | 2012 |
|
RU2614254C2 |
| TUMOUR MARKER, REAGENT FOR DETECTING METHYLATION, KIT AND APPLICATION THEREOF | 2019 |
|
RU2770928C1 |
| TUMOUR MARKER, REAGENT FOR DETECTING METHYLATION, KIT AND APPLICATION THEREOF | 2019 |
|
RU2775177C1 |
| SET OF OLIGONUCLEOTIDE PRIMERS AND FLUORESCENTLY LABELLED PROBES FOR IDENTIFYING THE EPIGENETIC MARKERS OF CERVICAL CANCER | 2021 |
|
RU2760573C1 |
| METHOD FOR DETERMINATION OF METHYLATION OF COLORECTAL CANCER TUMOR MARKER GENES REGULATORY REGIONS PUCGPY SITES BY GLAD-PCR ANALYSIS, AND SET OF OLIGONUCLEOTIDE PRIMERS AND FLUORESCENCE-LABELLED PROBES FOR IMPLEMENTATION OF THIS METHOD | 2016 |
|
RU2630669C1 |
| METHOD OF CYTOSINE METHYLATION DETECTION IN DNA SAMPLES | 2002 |
|
RU2332462C2 |
| IMMUNOSTIMULATING NUCLEIC ACIDS | 2000 |
|
RU2245149C2 |
| COMBINATION FOR SCREENING OF RECTAL AND COLON CANCER, AS WELL AS PROGRESSIVE ADENOMA AND USE OF COMBINATION | 2019 |
|
RU2812023C2 |
